What Spasmaverine Treats: Main Uses and Benefits

Spasmaverine, containing the active ingredient mebeverine, is an antispasmodic medication applied across domains where additional symptomatic support is needed in the gastrointestinal tract. The primary therapeutic domain is considered relevant in conditions characterized by periods of heightened symptoms, primarily Irritable Bowel Syndrome (IBS).

This medicine is commonly used across conditions presenting with acute episodes, including related functional bowel disorders such as chronic irritable colon and spastic colitis. It provides support that helps ease the overall symptom burden linked to organ-specific functional stress. It is commonly used to help with symptoms of increased neurological or muscular activity, assisting with symptom clusters that may become intense or disruptive, specifically colicky abdominal pain, cramps, bloating, and flatulence.

It is considered relevant in clinical settings that involve acute or unstable symptom patterns, providing supportive relief when symptoms intensify. As a patient benefit, this support contributes to easing the overall symptom load during periods of heightened symptoms.

Mebeverine is commonly used to help with the symptoms of these conditions such as: colicky abdominal pain and cramps, persistent, non-specific diarrhoea, and flatulence.

---

Quick Fact: Supports easing Stomach Cramps

Eligibility Map: Who Can and Cannot Use Spasmaverine

The eligibility profile for Spasmaverine (Alverine Citrate) is defined by official regulatory documents, which establish clear restrictions based on age, physiological status, and underlying medical conditions.

Eligibility Scope

Category	Official Regulatory Status
Populations for whom use is allowed	Adults and Adolescents aged 12 years and above.
Populations for whom use is not recommended	Children below the age of 12 years.
Populations for whom use is contraindicated	Patients with known Hypersensitivity to alverine citrate, Intestinal Obstruction, or Paralytic Ileus.

Condition-Specific Restrictions

Category	Regulatory Status
Pregnancy and Lactation	Contraindicated during both periods.
Eligibility-related Restrictions	Medical consultation is required for patients aged 40 or over with new symptoms, severe constipation, unexplained weight loss, or blood passed from the bowel, as these define conditional non-eligibility for self-medication.

Official Eligibility Summary: Use is generally permitted for individuals 12 years and older, but it is strictly prohibited in cases of bowel obstruction, severe allergy, pregnancy, or lactation. The presence of specific severe or unexplained symptoms mandates professional advice before use.

Spasmaverine, containing the active ingredient Alverine Citrate, has a highly focused interaction profile as presented in official regulatory documentation, with a noted absence of documented clinically significant interactions.

Documented Interaction Profile

Interaction Entity Map (High-Level)	Official Regulatory Finding
Contraindicated Combinations	None documented. Regulatory documents do not list any medicinal products prohibited due to a drug–drug interaction risk.
Pharmacokinetic Interactions	None documented. Official prescribing information does not describe specific enzyme-mediated or transporter-based interactions that result in a formal restriction.
Food, Alcohol, Herbal Products	None documented. No official restrictions or warnings are stated for co-administration with food, alcohol, or herbal products.
Timing / Separation Rules	None documented. No mandatory rules require Alverine Citrate administration to be separated in time from any other medicinal product.

Resulting Interaction Structure

Official interaction statements across regulatory sources consistently state that no clinically significant interactions with other medicinal products are known or formally documented. This means that no agents are formally identified by regulatory authorities as modifying the drug’s exposure or effect through specific metabolic or pharmacodynamic pathways.

The regulatory label does not define any mandatory constraints for co-administration, reflecting the drug’s minimal official interaction structure.

Direct Smooth Muscle Relaxation

This mechanism involves the drug's direct action on the smooth muscle cells primarily within visceral structures such as the gastrointestinal tract and uterus. Spasmaverine engages processes that regulate overactive contractile activity, resulting in the attenuation of smooth muscle contraction frequency and force and decreased basal muscle tone in these visceral structures.

---

Inhibition of Calcium Influx and Protein Sensitivity

At the molecular level, the drug acts as a non-specific inhibitor of the influx of extracellular calcium ions (Ca^2+) into smooth muscle cells. This activity suppresses the sensitivity of intracellular contractile proteins to Ca^2+. This modification acts to constrain downstream signaling induced by hyperactive mediators, driving a shift in the resting membrane potential within targeted contractile pathways, which limits cellular excitability.

---

Serotonin Receptor Modulation

Spasmaverine also exhibits interaction with the 5-hydroxytryptamine receptor 1A (5-HT1A), functioning as a partial agonist. By engaging with mechanisms that regulate receptor-mediated signaling in the enteric nervous system, the drug modulates activity within pathways driven by distinct signaling patterns that affect enteric neuronal signaling and efferent motor responses.

How to Use Spasmaverine

Spasmaverine, which contains Alverine Citrate, is administered exclusively by the oral route and is supplied as a hard capsule. Usage involves specific parameters regarding dosage, frequency, and the method of intake.

---

Dosing and Frequency

The standard dose for adults, including older adults, is set at 60 mg or 120 mg of Alverine Citrate per intake. This dose is scheduled to be taken one to three times daily, which limits the maximum total daily exposure to 360 mg. This usage pattern defines the general frequency and schedule. There is no requirement for specific timing in relation to meals.

---

Administration Method and Constraints

The medicine is a hard capsule that must be swallowed whole with water. This method is essential, as the capsule must not be crushed, broken, or chewed. Maintaining the integrity of the hard capsule is a core procedural requirement for use. No preparation or dilution steps are needed prior to administration of this specific oral form.

---

Population Rules and Treatment Duration

The medicine is not recommended for administration to children under the age of 12 years. The standard adult dosing regimen is applied to older adults without the requirement for dose modification. Furthermore, the use protocol includes a procedural constraint on duration: a review of treatment is required if there is no improvement in symptoms after two weeks of administration. This time-related condition structures the initial course of use.

Research Evidence / Overview of Studies for Spasmaverine

---

Evidence for Use in Irritable Bowel Syndrome (IBS)

Research has primarily evaluated the use of Alverine Citrate (the active component of Spasmaverine) in adult patients diagnosed with Irritable Bowel Syndrome (IBS). The types of studies used in research exploring how symptoms change over time include short-term, double-blind trials, which compare the drug to an inactive substance (placebo), alongside systematic reviews. The research examined outcomes related to physical discomfort, specifically measuring changes in abdominal pain (severity and frequency scores), and monitoring patient-reported changes in overall global symptoms.

In these studies, which included patients often defined by standardized criteria, findings describe patterns observed over study periods typically lasting between four to twelve weeks. However, findings were mixed across various studies; some trials involving the single-ingredient Alverine formulation did not show a measurable difference compared to the placebo response. This is often linked to the challenge that studies of conditions characterized by fluctuating or episodic manifestations like IBS often have a high placebo response, where changes in symptoms are measured even when receiving an inactive substance.

Evaluating Findings from Single-Ingredient vs. Combination Trials

The evidence landscape is associated with the fact that Alverine was studied for this use as a combination product with Simeticone, which is another ingredient added to the combination product. In these combination product trials, the data show patterns related to symptom measures that were observed when compared to placebo. The combination product reported statistically distinct measurements compared to placebo on endpoints such as the measure of abdominal pain/discomfort and changes in global symptoms.

---

Long-Term Research and Follow-up Durations

Research has primarily focused on episodes where symptoms become more noticeable, with trials often observing responses over defined time intervals that are short-term (four weeks) or intermediate (three months). However, the long-term effects are not fully established in the publicly available regulatory research. Follow-up durations were limited in many studies, meaning that data for long-term outcomes or the durability of the reported effects over many months or years remain insufficient.

---

Key Uncertainties and Research Gaps

The available evidence highlights what is known — and what is still uncertain — about Alverine Citrate. One key uncertainty stems from the mixed findings reported across the different studies, particularly when comparing the single-ingredient formulation to placebo. The evidence quality varies across studies, and many trials face the methodological issue of the high placebo response that can impact the clarity of the findings. Findings describe group patterns, not personal outcomes, and research does not determine whether an individual will respond similarly.

How to Store and Dispose of Spasmaverine

Official regulatory guidelines define strict environmental requirements to maintain the stability and shelf-life of Spasmaverine (Mebeverine).

Storage Conditions

Requirement	Official Instruction
Temperature	Store below 30 C.
Protection	Keep in the original package, protected from light and moisture.
Stability	Shelf-life is typically 3 to 5 years when stored as directed.

Disposal Instructions

Disposal must follow the instructions on the product labeling or government-approved guidelines for unused or expired medicines. It is recommended to use local pharmaceutical drug take-back programs when available. If a take-back program is not accessible, the product may be safely discarded in household trash after being mixed with an undesirable substance (such as dirt or coffee grounds) and sealed in a bag.

Do not flush Spasmaverine down a toilet or pour it down a sink or drain unless specifically authorized by the product's official labeling.